Cannabinoids for rheumatic diseases: anti-inflammatory potential but lacking rigorous evidence | Research

The takeaway

Cannabinoids have anti-inflammatory and pain-relieving properties that could benefit rheumatic disease patients, but systematic reviews of their clinical use are outpacing the actual randomized controlled trials.

Rheumatology patients, clinicians in pain management, and medical cannabis policy researchers.

Reviews outpacing trials, often reaching conflicting conclusions

What the researchers found

Cannabinoids may help rheumatic diseases through anti-inflammatory/immunomodulatory activity and pain management. However, reviews are being published faster than trials, often reaching conflicting conclusions. The evidence for efficacy is limited and some data suggest potential harms. Safety concerns include driving risks, workplace safety, and pediatric intoxication.

Why it matters

Many rheumatology patients use or are curious about cannabis, especially for chronic pain. This review highlights that the enthusiasm has outpaced the evidence, and cannabis was often legalized without going through standard regulatory approval.

The numbers in context

Systematic review publications outpacing RCTs. Reviews reach conflicting conclusions about efficacy and safety.

How the study worked

Narrative review discussing advantages and limitations of cannabis for rheumatic conditions, including analysis of the imbalance between reviews and primary research.

What this study cannot tell us

Narrative review. The fundamental problem it identifies (more reviews than trials) means any conclusions are built on a thin foundation.

How to read the evidence

Moderate: balanced narrative review that transparently identifies the limitations of the evidence base.

When this study was published

Published in 2019.

The bigger picture

Chronic pain is the unmet need driving cannabis interest in rheumatology. Unlike inflammation, which has many treatment options including biologics, chronic pain has fewer effective options, making cannabis an attractive but unproven alternative.

Questions still open

Will future RCTs confirm or refute the benefits suggested by preliminary data? Which rheumatic conditions are most likely to benefit from cannabinoids? Can cannabinoids be integrated safely alongside immunomodulatory biologics?

Common questions

Can cannabis help arthritis pain?

There is theoretical support from cannabinoid pharmacology and some preliminary data, but rigorous clinical trials specifically for rheumatic pain are lacking.

Why are there more reviews than actual studies?

It is easier and faster to write a review of existing data than to conduct a new clinical trial. The intense interest in medical cannabis has created an incentive to publish reviews even when the underlying evidence is thin.

Read the original research

Cannabinoids in the treatment of rheumatic diseases: Pros and cons.

Autoimmunity reviews, 18(12), 102409

View on PubMed ↗Publisher’s paper ↗

Citation

Sarzi-Puttini, Piercarlo; Ablin, Jacob; Trabelsi, Adva; Fitzcharles, Mary-Ann; Marotto, Daniela; Häuser, Winfried. (2019). Cannabinoids in the treatment of rheumatic diseases: Pros and cons.. Autoimmunity reviews, 18(12), 102409. https://doi.org/10.1016/j.autrev.2019.102409